Volume 5.36 | Sep 12

Mammary Cell News 5.36 September 12, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
ErbB3 Downregulation Enhances Luminal Breast Tumor Response to Antiestrogens
Since breast cancer phenotypes may reflect biological traits of the mammary epithelial cells from which they originate, investigators tested the hypothesis that erythroblastosis oncogene B3 (ErbB3) drives luminal breast cancer growth. They found higher ERBB3 expression and more frequent ERBB3 gene copy gains in luminal A/B breast cancers compared with other breast cancer subtypes. [J Clin Invest]
| Press Release
[Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.
PUBLICATIONS (Ranked by impact factor of the journal)

Erythropoietin Activates Cell Survival Pathways in Breast Cancer Stem-Like Cells to Protect Them from Chemotherapy
Investigators found that breast cancer stem-like cells (BCSC) isolated from patient tumors express the erythropoietin (EPO) receptor and respond to EPO treatment with increased proliferation and self-renewal. Importantly, EPO stimulation increased BCSC resistance to chemotherapeutic agents and activated cellular pathways responsible for survival and drug resistance. [Cancer Res] Abstract

A New Platinum(II) Compound Anticancer Drug Candidate with Selective Cytotoxicity for Breast Cancer Cells
To confirm that [Pt(O,O′-acac)(γ-acac)(DMS)] has the potentiality for therapeutic intervention, researchers studied its effects in primary cultured epithelial breast cells obtained from cancers and also from the corresponding histologically proven non-malignant tissue adjacent to the tumor. [Cell Death Dis] Full Article

Mammary Carcinoma Cell Derived Cyclooxygenase 2 Suppresses Tumor Immune Surveillance by Enhancing Intratumoral Immune Checkpoint Activity
Mammary tumor onset and multiplicity were examined in ErbB2 transgenic mice that were deficient in mammary epithelial cell cyclooxygenase 2 compared to wild type. Tumors were analyzed by real time PCR, immune-staining and flow cytometry for proliferation, apoptosis, angiogenesis and immune microenvironment. [Breast Cancer Res] Abstract | Full Article

Disulfiram Targets Cancer Stem-Like Cells and Reverses Resistance and Cross-Resistance in Acquired Paclitaxel-Resistant Triple-Negative Breast Cancer Cells
Scientists found that chemoresistant MDA-MB-231PAC10 cells are highly cross-resistant to paclitaxel, cisplatin, docetaxel and doxorubicin. The MDA-MB-231PAC10 cells are quiescent with significantly longer doubling time. This may be caused by high expression of p21Waf1. [Brit J Cancer] Abstract

Leptin Receptor Maintains Cancer Stem-Like Properties in Triple Negative Breast Cancer Cells
The authors tested the hypothesis that the Leptin Receptor (LEPR), expressed in mammary cancer cells, is necessary for maintaining cancer stem cell-like and metastatic properties. They silenced LEPR via shRNA lentivirus transduction and determined that expression of stem cell self-renewal transcription factors NANOG, SOX2, and OCT4 are inhibited. [Endocr-Relat Cancer] Abstract

Progesterone Receptor and Stat5 Signaling Crosstalk through RANKL in Mammary Epithelial Cells
Scientists used a primary mouse mammary epithelial cell culture system to define the molecular mechanism by which progesterone regulates the expression of target gene effectors of proliferation including the paracrine factor RANKL. [Mol Endocrinol] Abstract

Sulforaphane Inhibits Mammary Adipogenesis by Targeting Adipose Mesenchymal Stem Cells
The authors examined the role of mesenchymal stem cell-differentiated adipocytes on breast cancer cell migration, and tested the effects of sulforaphane on adipocyte-breast cancer cell interaction. [Breast Cancer Res Treat] Abstract


Prediction of Late Distant Recurrence in Patients with Estrogen-Receptor-Positive Breast Cancer: A Prospective Comparison of the Breast-Cancer Index (BCI) Assay, 21-Gene Recurrence Score, and IHC4 in the TransATAC Study Population
Scientists compared the prognostic ability of the BCI assay, 21-gene recurrence score, and an immunohistochemical prognostic model (IHC4) for both early and late recurrence in patients with estrogen-receptor-positive, node-negative disease who took part in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) clinical trial. [Lancet Oncol] Abstract | Press Release

Phase I Trial Combining Temozolomide plus Lapatinib for the Treatment of Brain Metastases in Patients with HER2-Positive Metastatic Breast Cancer: The LAPTEM Trial
The authors assessed the combination of lapatinib and temozolomide as treatment for patients with HER2-positive breast cancer and brain metastases. [Ann Oncol] Abstract

Loss of HER2 Positivity and Prognosis after Neoadjuvant therapy in HER2-Positive Breast Cancer Patients
Investigators evaluated the prognostic impact of HER2 loss in patients with HER2-positive disease treated with neoadjuvant therapy with or without anti-HER2 agents. [Ann Oncol] Abstract

Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
Biology and Therapeutic Potential of PI3K Signaling in ER+/HER2-Negative Breast Cancer
The authors summarize the recent findings in the cause-and-effect of PI3K pathway aberration and endocrine sensitivity, especially the crosstalk with the estrogen receptor α (ER) pathway. Potential therapeutic approaches based on these findings are also discussed. [Breast] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Researchers to Identify Genetic Biomarkers for Aggressive Breast Cancer
The Avon Foundation for Women has awarded a $300,000 grant to Dolores Di Vizio, MD, PhD, associate professor in the Department of Surgery and the Department of Pathology and Laboratory Medicine and a member of the Cancer Biology and Urologic Oncology Research Programs at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute to advance scientific research in aggressive breast cancer. [Cedars-Sinai] Press Release

Oncothyreon Announces Initiation of Phase I Trial of ONT-380 in Combination with Trastuzumab in Patients with Brain Metastases from HER2+ Breast Cancer
Oncothyreon Inc. announced the initiation of an investigator-sponsored trial of ONT-380 in combination with trastuzumab (Herceptin®) in patients with brain metastases from HER2+ breast cancer. The trial is being conducted under the sponsorship of the Dana-Farber Cancer Institute, Boston, Massachusetts. [Oncothyreon Inc.] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 3rd Annual Best of Oncology East Conference
November 29, 2013
Toronto, Canada

NEW Kyoto Breast Cancer Consensus Conference
February 20-22, 2013
Kyoto, Japan

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Fellow – Breast Cancer Biology (Stephenson Cancer Center at the University of Oklahoma)

Research Technician – Cancer Immunotherapy (The Netherlands Cancer Institute)

Postdoctoral Position – Metastasis of Human Breast Cancer Subtypes (Weizmann Institute of Science)

Research Assistant – Cellular Pathways Involved in Oncogenic Transformation of Breast Epithelial Cells (Mount Sinai School of Medicine)

Senior Research Assistant/Postdoctoral Researcher- Tumor Biology/Molecular Imaging (RCSI Royal College of Surgeons in Ireland)

Postdoctoral Position – Breast Cancer Signaling (Weizmann Institute of Science)

PhD Studentship – c-Met Pathway in Trastuzumab Resistant Breast Cancer (Barts Cancer Institute, Queen Mary University of London)

Postdoctoral Fellow in Breast Cancer – (Bellvitge Biomedical Research Institute [IDIBELL])

Faculty Position – Detection and Diagnosis of Solid Tumors (Stanford University)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mammary Cell News: Archives | Events | Contact Us